Exciting time to be doing research in GCA! Over half a dozen ongoing RCTs Challenging to recruit enough patients given (1) competing trials (2) reticence to join a trial when tocilizumab (standard of care) is available #ACR22 #Vasculitis22 @RheumNow https://t.co/mJm69gH4N9